Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data
Objective: To examine individual responses to pimavanserin in patients with Parkinson’s disease psychosis (PDP) initiating treatment <6 vs ≥6 months and <12 vs ≥12 months…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Demographic Features, QTc Interval and Psychosis in Military Veterans with Parkinson’s disease (PD)
Objective: To compare certain key demographic features and QTc intervals in groups of PD military Veterans with and without psychosis. Background: Psychosis is a disabling…Refining the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS): Cognitive Interview Results from an International Study
Objective: To assess the face and content validity of the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS), a new under-developing Clinical…Trends in U.S. Drug Use Among Hospitalized Parkinson’s Patients Experiencing Delirium
Objective: To examine drug use trends among hospitalized Parkinson’s disease (PD) patients in the U.S. and to assess the association between PD medications and delirium.…Predicting the Cognitive-Psychiatric Phenotype of Parkinson’s Disease
Objective: Predict PD patient’s clinical scores from brain activity. Inform on which assessments capture true changes in cortical dynamics caused by PD and explain those…Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study
Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report
Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies
Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…
- 1
- 2
- 3
- …
- 13
- Next Page »